NDAORALTABLETPriority Review
Approved
Aug 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
3/8 — Basic
Priority Review
MEVACOR (lovastatin) by Merck & Co. is hydroxymethylglutaryl-coa reductase inhibitors [moa]. First approved in 1987.
Drug data last refreshed 1h ago
Mechanism of Action
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers
Started Nov 2015
20 enrolled
Lipid Metabolism Disorder
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
Started Dec 2009
250 enrolled
MelanomaMalignant Melanoma
Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
Started Sep 2009
44 enrolled
Neurofibromatosis 1
A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Started Jul 2009
146 enrolled
Neurofibromatosis Type 1
Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis
Started Nov 2007
64 enrolled
Rheumatoid Arthritis
Worked on MEVACOR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.